Shoulder Innovations Announces Full Commercial Launch of the InSet™ 70 Humeral Stem

Shoulder Innovations (NYSE:SI) has announced the full commercial launch of its InSet™ 70 Humeral Stem across the United States, expanding its I-Series humeral stem product line.

Rhea-AI Summary

Shoulder Innovations (NYSE:SI) has announced the full commercial launch of its InSet™ 70 Humeral Stem across the United States, expanding its I-Series humeral stem product line. The new implant, complementing the InSet™ 95 launched in 2024, is designed for both anatomic and reverse shoulder arthroplasty procedures.

The InSet™ 70 is indicated for various clinical applications, including non-inflammatory degenerative joint disease, rheumatoid and traumatic arthritis, and functional deformity correction. For reverse procedures, it's also indicated for irreparable cuff tears with or without arthritis and device revisions with sufficient bone stock. The device offers bone-sparing utility while maintaining excellent initial fixation and simple workflow.

Argus Sep 22 session

-2.36% close to close Open Argus

Details

News Market Reaction – SI

On Sep 22, the day this news came out, SI closed 2.36% below the previous close.

Data tracked by StockTitan Argus for the Sep 22 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expansion of the I-Series Humeral Stem Product Line Further Strengthens Robust Shoulder Arthroplasty Portfolio

GRAND RAPIDS, Mich., Sept. 22, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the full commercial launch of the InSet™ 70 Humeral Stem ("InSet™ 70"). The introduction of the InSet™ 70 represents an expansion of the company's I-Series humeral stem product line, which first launched with the InSet™ 95 humeral stem in 2024.

This expansion of the I-Series Humeral Stem product line further strengthens a robust Shoulder Arthroplasty portfolio.

"The InSet™ 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule," said Rob Ball, CEO of Shoulder Innovations. "SI has a strong history of innovation, and the InSet™ 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant."

Indicated for use in both anatomic and reverse shoulder arthroplasty, the InSet™ 70 addresses a broad range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.

"Featuring the same excellent initial fixation and simple workflow as the longer InSet™ 95, the InSet™ 70 offers the added benefit of bone-sparing utility, making it a compelling offering in the shoulder care space," said Galen Kam, MD. "Essentially, this product affords all the advantages of a larger stem in a smaller, bone-preserving form factor."

"The InSet™ 70 provides my patients with superb humeral fixation within the reverse total shoulder platform, delivering optimized biomechanics and supporting improved shoulder function," said Matthew Pifer, MD.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact 
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-announces-full-commercial-launch-of-the-inset-70-humeral-stem-302562301.html

SOURCE Shoulder Innovations

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the InSet™ 70 Humeral Stem by Shoulder Innovations (NYSE:SI)?

The InSet™ 70 is a bone-sparing humeral stem implant designed for both anatomic and reverse shoulder arthroplasty procedures, offering excellent initial fixation and simple workflow.

What conditions can be treated with the InSet™ 70 Humeral Stem?

The InSet™ 70 can treat non-inflammatory degenerative joint disease, osteoarthritis, avascular necrosis, rheumatoid and traumatic arthritis, functional deformity, and irreparable cuff tears with or without arthritis.

How does the InSet™ 70 differ from the InSet™ 95 Humeral Stem?

While maintaining the same excellent initial fixation and workflow as the InSet™ 95, the InSet™ 70 offers bone-sparing utility in a smaller form factor, making it more versatile for certain procedures.

When did Shoulder Innovations launch the InSet™ 70 Humeral Stem?

Shoulder Innovations launched the InSet™ 70 Humeral Stem commercially across the United States on September 22, 2025, ahead of schedule.